Cryosite Limited (ASX:CTE)

Australia · Delayed Price · Currency is AUD

1.220

+0.020 (1.67%)

At close: Oct 26, 2026

Market Cap	59.55M +10.9%
Revenue (ttm)	16.70M +18.3%
Net Income	2.24M +18.6%
EPS	0.04 +14.8%
Shares Out	48.81M
PE Ratio	28.11
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	31
Open	1.220
Previous Close	1.200
Day's Range	1.220 - 1.220
52-Week Range	1.000 - 1.400
Beta	0.15
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 26, 2026

About Cryosite

Cryosite Limited provides outsourced clinical trials logistic services in Australia. It operates through Ambient, cold, and frozen; Ultra-frozen and cryogenic; and Cord Blood segments. The Ambient, cold, and frozen segment provides good manufacturing practice (GMP) clinical trial materials, scheduled medicines, controlled drug storage, clinical ancillary supplies, medical devices, and commercial products with strict temperature requirements. The Ultra-frozen and cryogenic segment offers advanced therapy medicinal products (ATMPS), such as cell ... [Read more]

Industry Diagnostics & Research

Sector Healthcare

Founded 1999

Employees 27

Stock Exchange Australian Securities Exchange

Ticker Symbol CTE

Full Company Profile

Financial Performance

In fiscal year 2026, Cryosite's revenue was 16.70 million, an increase of 18.31% compared to the previous year's 14.12 million. Earnings were 2.24 million, an increase of 18.63%.

Financial Statements